LuMind IDSC and The Arc of Northeast collaborated on an OpEd that was recently published…
Kate O’NeillSeptember 18, 2023
Five takeaways for the Down syndrome community: Updates on accessing the new Alzheimer’s drugsLuMind IDSC…
Kate O’NeillJuly 7, 2023
LuMind IDSC issues statement following FDA full approval of Leqembi™ to treat early-stage Alzheimer’s disease …
Kate O’NeillJuly 7, 2023
Study Finds Assistive Technology Has Positive Outcomes for Children with Down Syndrome and Their Caregivers …
Kate O’NeillJune 2, 2023
Seeking to rectify existing federal and state policies which prevent people with intellectual disabilities from…
Kate O’NeillJune 1, 2023
Pharmaceutical company Eli Lilly today announced results of a phase III clinical trial that proves…
Kate O’NeillMay 3, 2023
At the end of March, the US Food & Drug Administration approved Inspire’s Hypoglossal Nerve…
Kate O’NeillMarch 29, 2023
"Alzheimer's meds are here. But for the Down syndrome community, it's still the 1980s" by…
Kate O’NeillMarch 2, 2023
2/22/2023 (Burlington, MA) – Today the LuMind IDSC Foundation, a leading national Down syndrome research…
Kate O’NeillFebruary 23, 2023